Paloxi 0.075 mg/1.5 ml is an intravenous injection formulated with Palonosetron Hydrochloride, a potent and selective 5-HT₃ receptor antagonist. Manufactured by Beacon Pharmaceuticals PLC in Bangladesh, this medication is primarily used to prevent and treat nausea and vomiting associated with:
Chemotherapy-induced nausea and vomiting (CINV): Effective against both acute and delayed phases.
Radiotherapy-induced nausea and vomiting (RINV).
Postoperative nausea and vomiting (PONV): Provides relief for up to 24 hours following surgery.